-
Tositumomab is a
murine monoclonal antibody which targets the CD20
antigen produced in
mammalian cell. It was
combined with iodine-131 to
produce a radiopharmaceutical...
-
targeting agent. Bexxar, a
radioligand therapy using the
radioisotope I-131+
Tositumomab (a
murine monoclonal antibody) and binding/targeting the
ligand CD20...
-
conjugated to yttrium-90. In 2003, the FDA
approved the
tositumomab/iodine (131I)
tositumomab regimen (Bexxar),
which is a
combination of an iodine-131...
- is
unique to the
neoplasm or is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy...
-
thyroid cancer Yttrium-90-ibritumomab
tiuxetan (Zevalin) and Iodine-131-
tositumomab (Bexxar)
Refractory lymphoma 131I-MIBG (metaiodobenzylguanidine) Neuroendocrine...
- chosen, as
their high
immunogenicity promotes rapid tumor clearance.
Tositumomab is an
example used for non-Hodgkin's lymphoma.[citation needed] Antibody-directed...
- arthritis,
lupus nephritis etc.
Tosatoxumab mab
human Staphylococcus aureus Tositumomab Bexxar mouse CD20 Y
follicular lymphoma Tovetumab mab
human PDGFRA cancer...
- (Glofitamab
Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin)...
- rituximab, ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan,
tositumomab, and ublituximab,
which are all
active agents in the
treatment of all...
- and
radioimmunotherapy with 90Y
ibritumomab tiuxetan (Zevalin) & 131I
tositumomab (Bexxar)
therapy of low-grade non-Hodgkin's lymphoma. 188Re (Rhenium)...
